<sup>18</sup>F-氟脱氧葡萄糖PET在淋巴瘤中的应用价值

张悦; 高硕

¹⁸F-氟脱氧葡萄糖PET在淋巴瘤中的应用价值

张悦 , 高硕

文章导航 > 国际放射医学核医学杂志 > 2007, 31 > 5: (292-295)

引用本文:

Citation:

¹⁸F-氟脱氧葡萄糖PET在淋巴瘤中的应用价值

张悦,
高硕

300052 天津, 天津医科大学总医院PET-CT中心
中图分类号: R817.4

The value of ¹⁸F-fluorodeoxyglucose PET in lymphomas

ZHANG Yue,
GAO Shuo

PET-CT Center, General Hospital of Tianjin Medical University, Tianjin 300052, China
CLC number: R817.4

摘要: 淋巴瘤的发病率逐年升高,¹⁸F-氟脱氧葡萄糖(¹⁸F-FDG)PET作为一种全身性功能代谢显像手段在淋巴瘤的诊断、分期、治疗方案的选择、疗效的评价及残留肿块性质的判断方面具有重要价值,较常规影像学检查提供更多有价值的信息而得到临床的广泛认可,但仍有一定的假阳性及假阴性.
- 淋巴瘤 /
- 体层摄影术,发射型计算机 /
- 氟脱氧葡萄糖F18
Abstract: The morbidity of lymphomas increased yearly. As a whole-body functional metabolic imaging modality, ¹⁸F-FDG PET was very valuable in the diagnosing, staging, selecting treatment program, evaluating therapeutic response and differentiating residual mass. PET had been recognized as a helpful modality because it can provide much more additional information than conventional imaging. However, there was some false positive and false negative.
- Lymphomas /
- Tomography,emission-computed /
- FluorodeoxyglucoseF18
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin Disease:coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT?. Radiology, 2004, 232(3):823-829.
[2]	Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood, 2003, 101(10):3875-3876.
[3]	Spaepen K, Stroobants S, Dupont P, et al.[(18)F]FDG PET monitoring of tumour response to chemotherapy:does[(18)F]FDG uptake correlate with the viable tumour cell fraction?. Eur J Nucl Med Mol Imaging, 2003, 30(5):682-688.
[4]	Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglueose in sareoidosis. J Nuel Med, 1994, 35(10):1647-1649.
[5]	Tomas MB, Tronco GG, Karayalcin G, et al. FDG uptake in infectious mononucleosis. Clin Positron Imaging, 2000, 3(4):176.
[6]	Kaste SC, Howard SC, McCarville EB, et al. ¹⁸F-FDG-avid sites mimicking active disease in pediatric Hodgkin's. Pediatr Radiol, 2005, 35(2):141-154.
[7]	Hong SP, Hahn JS, Lee JD, et al. ¹⁸F-fluorodeoxyglucose positron emission tomography in the staging of malignant lymphoma compared with CT and ⁶⁷Ga scan. Yonsei Med J, 2003, 44(5):779-786.
[8]	Israel O, Keidar Z, Bar-Shalom R. Positron emission tomography in the evaluation of lymphoma. Semin Nucl Med, 2004, 34(3):166-179.
[9]	Kumar R, Maillard I, Schuster SJ, et al. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas. Radiol Clin North Am, 2004, 42(6):1083-1100.
[10]	Tatsumi M, Cohade C, Nakamoto Y, et al. Direct comparison of FDG PET and CT findings in patients with lymphoma:initial experience. Radiology, 2005, 237(3):1038-1045.
[11]	Fuster D, Chiang S, Andreadis C, et al. Can[¹⁸F]fluorodeoxyglu-cose positron emission tomography imaging complement biopsy re-sults from the iliac crest for the detection of bone marrow involve-ment in patients with malignant lymphoma?. Nuel Med Commun, 2006, 27(1):11-15.
[12]	Delbeke D, Martin WH, Morgan DS, et al. 2-deoxy-2-[F-18] fluoro-Dglucose imaging with positron emission tomography for initial staging of Hodgkin's disease and lymphoma. Mol Imaging Biol, 2002, 4(1):105-114.
[13]	Buchmann I, Reinhardt M, Elsner K, et al. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bieenter trial. Cancer, 2001,91(5):889-899.
[14]	Schoder H, Meta J, Yap C, et al. Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 200142(8):1139-1143.
[15]	Lowe VJ, Wiseman GA. Assessment of lymphoma therapy using (18) F-FDG PET. J Nuel Med, 2002, 43(8):1028-1030.
[16]	Yamane T, Daimaru O, ho S, et al. Decreased ¹⁸F-FDG uptake 1 day after initiation of chemotherapy for malignant lymphomas. J Nucl Med, 2004, 45(11):1838-1842
[17]	Castellucci P, Zinzani P, Nanni C, et al.¹⁸F-FDG PET early arier radiotherapy in lymphoma patients. Cancer Biother Radiopharm, 2004, 19(5):606-612.
[18]	Lavely WC, Delbeke D, Greer JP, et al. FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. Int J Radiat Oncol Biol Phys, 2003, 57(2):307-315.
[19]	Jerusalem G, Hustinx R, Beguin Y, et al. Positron emission tomography imaging for lymphoma. Curr Opin Oncol, 2005, 17(5):441-445.

[1]	赵德善 , 乔振华 . ¹⁸F-氟脱氧葡萄糖PET-CT在淋巴瘤中的应用价值. 国际放射医学核医学杂志, 2007, 31(3): 141-144.
[2]	宋少莉 , 黄钢 . ¹⁸F-氟脱氧葡萄糖PET监测实体瘤放化疗疗效的应用进展. 国际放射医学核医学杂志, 2007, 31(5): 284-288.
[3]	郑玉民 , 颜珏 . ¹⁸F-氟脱氧葡萄糖PET在恶性淋巴瘤中的应用. 国际放射医学核医学杂志, 2008, 32(6): 347-351.
[4]	段钰 , 邓小虎 , 徐迟峰 , 周海中 . 面部原发性外周T细胞淋巴瘤-非特指型¹⁸F-FDG PET/CT显像一例. 国际放射医学核医学杂志, 2017, 41(6): 455-457. doi: 10.3760/cma.j.issn.1673-4114.2017.06.014
[5]	萨日 , 赵红光 , 关锋 , 林承赫 . ¹⁸F-FDG PET/CT在弥漫性大B细胞淋巴瘤疗效评价中的临床价值. 国际放射医学核医学杂志, 2013, 37(1): 9-12. doi: 10.3760/cma.j.issn.1673-4114.2013.01.003
[6]	丁晓芳 , 肖晓燕 , 柳江燕 . PET/CT在结外NK/T细胞淋巴瘤诊治中的应用进展. 国际放射医学核医学杂志, 2021, 45(12): 789-794. doi: 10.3760/cma.j.cn121381-202012013-00111
[7]	陆东燕 , 丁恩慈 , 胡天鹏 , 沈婕 . ¹⁸F-FDG PET/CT在继发性肾淋巴瘤与肾脏免疫性疾病鉴别诊断中的价值. 国际放射医学核医学杂志, 2022, 46(3): 131-138. doi: 10.3760/cma.j.cn121381-202103019-00149
[8]	李剑明 , 李亚明 . 棕色脂肪组织与¹⁸F-氟脱氧葡萄糖PET. 国际放射医学核医学杂志, 2007, 31(4): 205-207,231.
[9]	杨吉刚 , 李春林 . ¹⁸F-氟脱氧葡萄糖PET及PET-CT在食管癌中的. 国际放射医学核医学杂志, 2007, 31(1): 31-33.
[10]	邢岩 , 赵晋华 . ¹⁸F-氟脱氧葡萄糖PET及PET-CT早期诊断肿瘤复发. 国际放射医学核医学杂志, 2007, 31(6): 341-344.